Tianjin Development Holdings Limited (Stock Code: 882) announced that on 19 November 2025, its indirect non-wholly owned subsidiary Tianjin Lisheng Pharmaceutical Co., Ltd. entered into the 11th Industrial Bank Wealth Management Agreement. Lisheng Pharmaceutical subscribed for a fixed income investment product managed by CIB Wealth Management Co., Ltd. and held under Industrial Bank Co., Ltd. in the principal amount of RMB30 million, equivalent to approximately HK$32.82 million.

According to the announcement, the product lacks principal guarantee, offers a floating return with an expected annualized rate of 1.90%–2.20%, and allows redemption by the subscriber during a specified period every six months. The company noted that the subscription has been funded through idle self-owned funds and is intended to improve returns without affecting business operations.

When assessed on a standalone basis, the transaction does not qualify as a notifiable transaction under Chapter 14 of the Listing Rules. However, because the company continues to hold previous subscriptions from Industrial Bank, those transactions are aggregated under Rule 14.22. With the highest applicable percentage ratio exceeding 5% but below 25% when combined, this latest subscription constitutes a discloseable transaction under the Listing Rules, requiring reporting and announcement.

Tianjin Development Holdings Limited primarily invests in utilities, pharmaceuticals, hotels, and electrical and mechanical businesses, alongside strategic and other investments. Lisheng Pharmaceutical is principally engaged in the production and sale of chemical drugs in the PRC, with the company holding an effective interest of approximately 34.11%. Industrial Bank Co., Ltd. is a licensed bank in the PRC listed on the Shanghai Stock Exchange, and CIB Wealth Management Co., Ltd. is its wholly owned subsidiary approved by the China Banking and Insurance Regulatory Commission.